Trevena is currently developing a novel sphingosine-1-phosphate (S1P) receptor modulator, TRV045, as a non-opioid treatment for various CNS disorders.
S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability.
Trevena's discovery efforts have provided innovative insight into the function of the S1P receptor, resulting in a family of compounds that are capable of engaging this receptor in a more selective manner that does not produce immunosuppression or alter lymphocyte trafficking. In a preclinical model of chemotherapy-induced peripheral neuropathy, TRV045 demonstrated activity with reduced associated lymphopenia.
|Program||Molecular Target||Therapeutic Target||Current Phase||PC||PH1||PH2||PH3||NDA||Now Approved|
|TRV045||S1P receptor||CNS disorders||PC||Oral PC in progress||PH1 not started||PH2 not started||PH3 not started||NDA not started||Now Approved not started|